CA2101241C — Liposome-encapsulated ciprofloxacin
Assigned to Minister of National Defence of Canada · Expires 1998-12-22 · 27y expired
What this patent protects
Despite its potency and broad spectrum antibacterial activity, the therapeutic effectiveness of ciprofloxacin is limited in that it has a short elimination half-life and its potency against some bacteria may be compromised by the ability of some intracellular bacteria to reside a…
USPTO Abstract
Despite its potency and broad spectrum antibacterial activity, the therapeutic effectiveness of ciprofloxacin is limited in that it has a short elimination half-life and its potency against some bacteria may be compromised by the ability of some intracellular bacteria to reside and multiply within the human host cells where they are protected from the antibiotic. These problems can be solved by encapsulating the antibiotic within the microscopic lipid vesicles called liposomes, which protect the drug from dilution and elimination from the body. Moreover, the liposome-encapsulated antibiotic is naturally taken up by phagocytic cells which results in the delivery of the drug to intracellular sites of infection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.